Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

54.74
Delayed Data
As of Feb 17
 +2.24 / +4.27%
Today’s Change
42.67
Today|||52-Week Range
85.83
+9.88%
Year-to-Date
Eli Lilly Is Great Stock to Buy Now
Feb 15 / TheStreet.com - Paid Partner Content
Mallinckrodt (MNK) Tops Earnings & Sales Estimates
Feb 07 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb 07 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close52.50
Today’s open52.52
Day’s range52.06 - 54.86
Volume2,778,363
Average volume (3 months)2,302,762
Market cap$5.7B
Dividend yield--
Data as of 4:02pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)+78.72%
Earnings growth (this year)--
Earnings growth (next 5 years)+7.42%
Revenue growth (last year)+1.01%
P/E ratio29.9
Price/Sales2.30
Price/Book1.11

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...+0.15+0.32%
VRXValeant Pharmaceutic...-0.18-1.11%
OPKOPKO Health Inc+0.06+0.69%
TAROTaro Pharmaceutical ...+1.51+1.31%
Data as of 4:01pm ET, 02/17/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)$1.63
Annual revenue (last year)$3.4B
Annual profit (last year)$548.0M
Net profit margin14.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark C. Trudeau
Senior Vice President-
Global Operations
Frank Scholz
Corporate headquarters
Chesterfield, Derbyshire

Forecasts


Search for Jobs